---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Rehabilitation and nutritional therapies"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Rehabilitation and nutritional therapies. Topics: EHDN international guideline: physiotherapy and exercise, EHDN international guideline: speech and language therapy and nutrition, EHDN international guideline: cognitive symptoms, Physical therapy clinical recommendations, and 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/rehabilitation-and-nutritional-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Rehabilitation and nutritional therapies

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Rehabilitation and Nutritional Therapies

<a id="topic-2.2.2.1.4-1"></a>

### EHDN international guideline: physiotherapy and exercise

> “Early referral to a physiotherapist is recommended in order to facilitate the development of a therapeutic relationship, promote sustainable exercise behaviors and ensure long-term functional independence.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.4-2"></a>

### EHDN international guideline: speech and language therapy and nutrition

> “Early referral to Speech and Language Therapists is recommended (Grade C)”
> “Good nutritional care is a fundamental element of the management of HD (Grade C)”
> “Early assessment by a dietitian or nutritionist, and regular timely reviews of nutritional needs are recommended.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.4-3"></a>

### EHDN international guideline: cognitive symptoms

> “Based on present knowledge, no pharmacological treatment is recommended for the treatment of cognitive symptoms.”

Source: [Bachoud-Lévi et al. (2019)](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2019.00710/full)

<a id="topic-2.2.2.1.4-4"></a>

### Physical therapy clinical recommendations

> “We recommend the following specific physical therapy interventions for people with HD: aerobic exercise (grade A evidence), alone or in combination with resistance training to improve fitness and motor function, and supervised gait training (grade A evidence) to improve spatiotemporal features of gait.”

Source: [Quinn et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7080285/)

<a id="topic-2.2.2.1.4-5"></a>

### German Neurological Society guideline: speech and occupational therapy

> “Therefore, involving speech therapists in the multidisciplinary care of HD patients is essential.”
> “Symptom-based psychosocial interventions such as psychological procedures, occupational therapy, and physical activity are recommended to stabilize and maintain everyday functions.”

Source: [Saft et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10652593/)

<a id="topic-2.2.2.1.4-6"></a>

### MDS evidence-based review: nonpharmacologic interventions

> “Similarly, no evidence was eligible to support the use of physiotherapy, occupational therapy, exercise, dietary, or surgical treatments.”

Source: [Ferreira et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34842303/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
